Payment overview · 2025
General Payments
$1,530.86
76 reported records · 20 companies
Healthcare provider profile · identity verified
Jonathan Mark Adelson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · GREENBELT, MD · NPI 1700864501
Verified facts
What the public records show
CMS Open Payments records show Jonathan Mark Adelson, M.D. received $1,530.86 in general payments during 2025 across 76 reported records.
Janssen Biotech, Inc. accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $219.59 | 14.3% | 10 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $191.85 | 12.5% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $185.84 | 12.1% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $137.16 | 9.0% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $110.60 | 7.2% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $98.59 | 6.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.87 | 6.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $86.56 | 5.7% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $83.02 | 5.4% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $78.05 | 5.1% | 4 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $37.76 | 2.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.62 | 2.4% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $32.88 | 2.1% | 2 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $24.59 | 1.6% | 1 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $23.75 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.96 | 1.3% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $19.72 | 1.3% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $17.40 | 1.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $17.31 | 1.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $14.74 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,450.87 | 75 |
| Education | $79.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $219.59 | 10 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $191.85 | 7 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $110.60 | 4 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $98.59 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $94.87 | 4 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $86.56 | 4 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $85.78 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $83.02 | 3 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $78.05 | 4 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $75.53 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $38.25 | 2 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $37.76 | 2 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $34.86 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $34.26 | 1 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $32.88 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $29.79 | 3 | 2025 |
Source payment records
|
|||||
| Iovera Normalized: iovera |
Device | Pacira Pharmaceuticals Incorporated | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| Zilretta Normalized: zilretta |
Drug | Pacira Pharmaceuticals Incorporated | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.53 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.53 | 2 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 242 | 67 |
| Gabapentin | Gabapentin | 230 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 180 | 44 |
| Methotrexate | Methotrexate Sodium | 150 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 38 |
| Methylprednisolone | Methylprednisolone | 120 | 47 |
| Prednisone | Prednisone | 113 | 32 |
| Lorazepam | Lorazepam | 112 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | 21 |
| Potassium Chloride | Potassium Chloride | 84 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 77 | 21 |
| Tramadol Hcl | Tramadol Hcl | 76 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 23 |
| Sulindac | Sulindac | 64 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 63 | 20 |
| Colchicine | Colchicine | 62 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | suppressed |
| Meloxicam | Meloxicam | 56 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 56 | 23 |
| Trazodone Hcl | Trazodone Hcl | 53 | 15 |
| Allopurinol | Allopurinol | 52 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 36 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Sulfasalazine | Sulfasalazine | 51 | 11 |
| Leucovorin Calcium | Leucovorin Calcium | 45 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 45 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 17 |
| Folic Acid | Folic Acid | 36 | suppressed |
| Leflunomide | Leflunomide | 36 | suppressed |
| Telmisartan | Telmisartan | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 18 |
| Celecoxib | Celecoxib | 33 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 20 |
| Rybelsus | Semaglutide | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | 12 |
| Topiramate | Topiramate | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Azathioprine | Azathioprine | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 23 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Losartan Potassium | Losartan Potassium | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 12 |
| Lisinopril | Lisinopril | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Furosemide | Furosemide | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Metaxalone | Metaxalone | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,530.86 · 76 records | Janssen Biotech, Inc. | ACTHAR, BENLYSTA, Bimzelx, COSENTYX, Evoke, Iovera, KEVZARA, KRYSTEXXA, Kineret, LUPKYNIS, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORENCIA, OTEZLA, Ocrevus Zunovo, PANZYGA, PEMGARDA, PURIFIED CORTROPHIN GEL, QULIPTA, RINVOQ, SAPHNELO, SKYRIZI, TAVNEOS, TONMYA, TREMFYA, UBRELVY, UPLIZNA, Wegovy, Zilretta | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error